Semaglutide Complete Guide 2026: Ozempic, Wegovy & Rybelsus Explained

What Is Semaglutide?

Semaglutide is a once-weekly injectable (and once-daily oral) medication that has fundamentally changed how medicine approaches type 2 diabetes and obesity. Sold under the brand names Ozempic, Wegovy, and Rybelsus, it belongs to a class of drugs called GLP-1 receptor agonists — molecules that mimic a naturally occurring gut hormone to regulate blood sugar, appetite, and body weight.

The clinical results have been striking: in the landmark STEP 1 trial, adults with obesity lost an average of 14.9% of their body weight at 68 weeks. In the SELECT cardiovascular outcomes trial — the largest obesity drug trial ever conducted — semaglutide reduced serious heart events by 20% in people with established cardiovascular disease who had never been diagnosed with diabetes. These numbers pushed semaglutide from blockbuster diabetes drug to one of the most prescribed medications in history.

This guide covers everything: how semaglutide works at the molecular level, the differences between each branded form, evidence-based dosing protocols, side effects (including the ones that matter most), the compounding pharmacy situation, and how semaglutide compares to tirzepatide — the newer dual-agonist that outperformed it head-to-head in 2025.

How Semaglutide Works: Mechanism of Action

The GLP-1 Receptor System

GLP-1 (glucagon-like peptide-1) is a hormone released by cells in your small intestine in response to food. It has a short half-life of only 1–2 minutes in the body because an enzyme called DPP-4 (dipeptidyl peptidase-4) rapidly degrades it. Its natural role is to signal fullness and regulate post-meal blood sugar.

Semaglutide shares 94% amino acid homology with native human GLP-1 but contains three key structural modifications that transform its pharmacokinetics:

1. Position 8 substitution (Aib for alanine): Protects the molecule from DPP-4 cleavage
2. Position 34 substitution (arginine for lysine): Prevents off-target receptor binding
3. C18 fatty acid chain at position 26: Enables binding to albumin in the bloodstream, dramatically reducing renal clearance

The result: a half-life of approximately 165 hours (~1 week), enabling the once-weekly subcutaneous dosing that defines Ozempic and Wegovy.

What GLP-1 Receptor Activation Does

GLP-1 receptors are found throughout the body, and activating them with semaglutide produces effects at multiple sites simultaneously:

Pancreas: Semaglutide stimulates insulin secretion from beta cells in a glucose-dependent manner — meaning it only triggers insulin release when blood glucose is actually elevated. This is why hypoglycemia risk is low when semaglutide is used without insulin or sulfonylureas. It simultaneously suppresses glucagon release from alpha cells, reducing the liver's glucose output.

Brain (hypothalamus): This is the weight-loss mechanism. Semaglutide activates POMC and CART neurons (the "fullness" signals) in the arcuate nucleus while inhibiting NPY and AgRP neurons (the "hunger" signals). The net effect is reduced appetite, altered food preferences, and prolonged satiety — not simply willpower. Patients consistently report that food becomes less compelling, and smaller portions feel satisfying.

Gut: Semaglutide slows gastric emptying — food transits from the stomach to the small intestine more slowly. This blunts postprandial blood sugar spikes and extends feelings of fullness. It is also the primary driver of the GI side effects (nausea, vomiting) that many patients experience early in treatment.

Ozempic, Wegovy, and Rybelsus: What's the Difference?

All three products contain semaglutide, but they differ in dose, delivery method, and FDA-approved indication:

Ozempic (FDA approved December 2017)

Subcutaneous injection, once weekly. Approved to improve glycemic control in adults with type 2 diabetes and to reduce cardiovascular events in adults with T2D and established CVD. Available in 0.5 mg, 1 mg, and 2 mg doses. The maximum maintenance dose for T2D is 2 mg/week.

Wegovy (FDA approved June 2021 for obesity; March 2024 for CV risk)

Subcutaneous injection, once weekly at a higher dose than Ozempic. Approved for long-term weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity. In March 2024, Wegovy became the first weight-loss drug ever approved to reduce cardiovascular events — a label expansion based on the SELECT trial. The maintenance dose is 2.4 mg/week. In August 2025, FDA also approved Wegovy for noncirrhotic MASH (metabolic-associated steatohepatitis) with moderate-to-advanced liver fibrosis.

Rybelsus (FDA approved September 2019)

The first oral GLP-1 receptor agonist approved in the United States. A once-daily tablet for type 2 diabetes. Because oral bioavailability of peptides is inherently low (~1%), Rybelsus uses a proprietary SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) technology to facilitate GI absorption. It must be taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before any food, drink, or other medication.

Dosing and Titration: The Step-Up Schedule

Semaglutide is always started at a low "initiation dose" and titrated upward over weeks to months. This slow escalation is essential for minimizing GI side effects — it is not a therapeutic dose; it is a tolerance-building phase.

Wegovy (Obesity) — 5-Step Escalation

If a patient cannot tolerate the 2.4 mg maintenance dose, it can be temporarily reduced to 1.7 mg. Each step requires a minimum of 4 weeks before escalating.

Ozempic (Type 2 Diabetes) — 4-Step Escalation

Rybelsus (Type 2 Diabetes, Oral) — 3-Step Escalation

Practical note on injections: Ozempic and Wegovy are injected subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites weekly. The injection can be given any day of the week, but it should be the same day each week. If you miss a dose by more than 5 days, skip it and resume on your next scheduled day.

Clinical Evidence: What the Trials Show

STEP Trials — Obesity (Wegovy 2.4 mg)

The STEP (Semaglutide Treatment Effect in People with Obesity) program is the most robust weight-loss drug evidence base in history:

• STEP 1 (68 weeks, N=1,961, non-diabetic adults): Average weight loss of 14.9% with semaglutide vs. 2.4% with placebo. 86.4% of semaglutide patients achieved at least 5% weight loss. Published in NEJM (Wilding et al., 2021).
• STEP 3 (with intensive behavioral therapy, 68 weeks): Weight loss of 16.0% vs. 5.7% with placebo + therapy — showing the drug adds substantially to lifestyle intervention.
• STEP 4 (withdrawal trial): Patients who lost weight on semaglutide then switched to placebo regained most of it, ending at −5.0% from baseline. Those who continued semaglutide maintained −17.4%. This underscores that semaglutide requires ongoing use to maintain results.
• STEP 5 (104 weeks, 2-year data): Weight loss of 15.2% at 2 years vs. −2.6% placebo. Published in Nature Medicine.

SUSTAIN Trials — Type 2 Diabetes

The SUSTAIN program enrolled over 8,000 adults with T2D across 7 phase 3 trials. Semaglutide 0.5 mg reduced HbA1c by 1.20–1.45% from baseline; the 1.0 mg dose reduced HbA1c by 1.50–1.80%. In SUSTAIN 6 — the cardiovascular outcomes trial — semaglutide reduced 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 26% relative risk reduction (HR 0.74; 95% CI 0.58–0.95) over 2.1 years in high-risk T2D patients.

SELECT Trial — The Landmark CV Outcomes Study

SELECT (published in NEJM, Lincoff et al., 2023) is arguably semaglutide's most consequential trial. It enrolled 17,604 participants — adults aged 45+ with established cardiovascular disease and obesity (BMI ≥27), none of whom had diabetes. Over a mean follow-up of 39.8 months:

• Major cardiovascular events: 6.5% (semaglutide) vs. 8.0% (placebo)
• 20% relative reduction in MACE (HR 0.80; 95% CI 0.72–0.90; p<0.001)
• CV death reduced by 15%; all-cause mortality reduced by 19%
• Average weight loss in the semaglutide group: 9.4%

This trial established that semaglutide's cardiovascular benefit extends beyond diabetic populations and is at least partly independent of weight loss alone — driving Wegovy's March 2024 cardiovascular label expansion.

Side Effects: What to Expect and What to Watch For

GI Side Effects (Most Common)

Gastrointestinal side effects are the most frequent reason patients discontinue or struggle with semaglutide, particularly during dose escalation:

• Nausea: 44% of Wegovy patients (vs. lower rates with placebo). Usually peaks during the first few weeks of each dose increase, then subsides.
• Diarrhea: ~30% of patients
• Vomiting: ~24%
• Constipation: ~24%
• Abdominal pain: ~20%

Approximately 95% of GI adverse events are mild to moderate. Strategies to minimize them include: eating smaller meals, avoiding high-fat/spicy foods during dose escalation, not lying down immediately after eating, and asking your provider about slowing the titration if symptoms are intolerable.

Gallbladder Disease

An underappreciated side effect. Semaglutide increases gallstone (cholelithiasis) risk, with Wegovy trials showing 1.6% incidence vs. 0.7% placebo. A meta-analysis in JAMA Internal Medicine found higher-dose semaglutide associated with a relative risk of 1.58 (95% CI: 1.13–2.22) for gallbladder and biliary disease. Patients should be aware of gallbladder symptoms — right upper quadrant pain, especially after meals — and report them to their provider.

Pancreatitis

Acute pancreatitis (including hemorrhagic and necrotizing forms) has been reported with semaglutide. The incidence is rare, but the consequences can be severe. Persistent, severe abdominal pain radiating to the back — with or without nausea/vomiting — should prompt immediate medical evaluation. If pancreatitis is confirmed, semaglutide should be discontinued permanently.

Thyroid C-Cell Tumors — Black Box Warning

All semaglutide labeling carries a Boxed Warning (the FDA's highest level of safety warning) regarding thyroid C-cell tumors. In rodent studies, semaglutide caused dose-dependent thyroid C-cell adenomas and carcinomas. Whether this risk extends to humans is unknown — human thyroid tissue has far fewer GLP-1 receptors than rodent thyroid — but the FDA cannot exclude the possibility.

Contraindication: Semaglutide is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should promptly report any neck lumps, hoarseness, or difficulty swallowing during treatment.

Gastroparesis Risk

GLP-1-mediated gastric slowing can, in some patients, progress to clinically significant gastroparesis — a condition where the stomach cannot empty properly. Symptoms (chronic nausea, bloating, early satiety, vomiting) overlap with common GI side effects, making it important to distinguish adaptation from a pathological response. The FDA has added gastroparesis to semaglutide's warning labels.

Cardiovascular: Diabetic Retinopathy (Ozempic)

In SUSTAIN 6, the semaglutide group had a higher rate of diabetic retinopathy complications (3.0% vs. 1.8% placebo), possibly related to rapid HbA1c reduction. Patients with pre-existing diabetic retinopathy should have ophthalmologic monitoring during treatment.

Compounded Semaglutide: What Patients Need to Know in 2025–2026

During the shortage period following Wegovy's 2021 approval — when demand vastly outstripped supply — the FDA's compounding regulations allowed 503A pharmacies and 503B outsourcing facilities to legally produce copies of shortage drugs, including semaglutide. Millions of patients accessed lower-cost compounded semaglutide through telehealth companies and compounding pharmacies.

That window has largely closed:

• February 21, 2025: FDA issued a Declaratory Order removing semaglutide from the national drug shortage list, finding that Novo Nordisk's production meets or exceeds demand.
• April 22, 2025: Deadline for 503A pharmacies to cease compounding semaglutide.
• May 22, 2025: Deadline for 503B outsourcing facilities.

The compounding industry pushed back hard. The Outsourcing Facilities Association filed a lawsuit challenging the shortage resolution; Novo Nordisk intervened in support of the FDA's position. Novo Nordisk also filed waves of lawsuits against compounders — including Hims & Hers and numerous telehealth platforms — alleging patent infringement, trademark violations, and false advertising. Courts have issued permanent injunctions barring multiple compounders from marketing their products as equivalent to Ozempic or Wegovy.

Key issues with compounded semaglutide that patients should understand:

• Compounded products are not FDA-approved and have not been reviewed for safety or efficacy
• FDA cannot verify the potency, sterility, or identity of compounded drugs
• Some compounders used semaglutide sodium or acetate salts — chemically distinct from the free-base form in approved products
• After April 22, 2025, most compounding of semaglutide is no longer legal under federal law

Patients who were on compounded semaglutide should work with their provider to transition to an FDA-approved branded product or discuss alternatives.

Semaglutide vs. Tirzepatide: Which Is More Effective?

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's rival GLP-1 drug — but with a key difference. Where semaglutide is a GLP-1 mono-agonist, tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activating both incretin pathways appears to synergize for greater weight loss and potentially better tolerability.

The definitive answer came in the SURMOUNT-5 trial, published in the NEJM in 2025 — the first head-to-head randomized comparison:

• Tirzepatide: −20.2% body weight at 72 weeks
• Semaglutide: −13.7% body weight at 72 weeks
• Tirzepatide produced 47% greater relative weight loss
• 31.6% of tirzepatide patients achieved ≥25% body weight loss vs. 16.1% semaglutide
• GI discontinuations: 2.7% (tirzepatide) vs. 5.6% (semaglutide) — suggesting tirzepatide may be better tolerated

What semaglutide has that tirzepatide lacks: a larger evidence base, more long-term cardiovascular outcome data (SELECT), and broader insurance coverage in many markets. The two drugs carry comparable list prices. For many patients, formulary access and insurance coverage will determine which drug they can access — not clinical preference alone.

Who Should Not Take Semaglutide

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide

Use with caution or avoid:

• History of pancreatitis: Most clinicians avoid GLP-1 RAs in patients with prior pancreatitis
• Pregnancy: Discontinue semaglutide at least 2 months before a planned pregnancy; stop immediately if pregnancy occurs; not for use during breastfeeding
• Severe GI disease (gastroparesis, severe IBD)
• Type 1 diabetes: Not approved or indicated
• Pre-existing diabetic retinopathy: Requires close ophthalmologic monitoring

The Bottom Line

Semaglutide is a genuine breakthrough in metabolic medicine. The evidence base — spanning tens of thousands of patients across STEP, SUSTAIN, SELECT, and PIONEER trials — documents meaningful, sustained reductions in body weight, blood sugar, and cardiovascular events that no previous drug class achieved simultaneously.

Its limitations are real: it requires ongoing use to maintain results, causes GI side effects particularly during titration, carries an important thyroid warning, and at list price remains expensive for many patients. It also now faces a formidable competitor in tirzepatide, which delivered ~47% greater weight loss in the 2025 head-to-head comparison.

But for the millions of people managing type 2 diabetes, obesity, or both — and especially those with elevated cardiovascular risk — semaglutide represents one of the most evidence-supported treatment options available in 2026. The compounding window has closed; the drug is now firmly in the territory of prescription-only, physician-supervised care.

References

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989–1002. (STEP 1)
2. Garvey WT, et al. "Two-Year Effects of Semaglutide in Adults with Overweight or Obesity." Nature Medicine. 2022. (STEP 5)
3. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM. 2023;389:2221–2232. (SELECT)
4. Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM. 2016;375:1834–1844. (SUSTAIN 6)
5. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022;387:205–216. (SURMOUNT-1)
6. SURMOUNT-5 Investigators. "Tirzepatide vs. Semaglutide: Head-to-Head Comparison in Obesity." NEJM. 2025. (SURMOUNT-5)